A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Northwestern University
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Inhibrx Biosciences, Inc
M.D. Anderson Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
Cantargia AB
Eastern Cooperative Oncology Group
Nektar Therapeutics
Augusta University
Augusta University
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Asan Medical Center
Hoosier Cancer Research Network
University of Arizona
Asan Medical Center
University of Southern California
M.D. Anderson Cancer Center
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company